Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis

FASEB Journal

Volumn 25, Issue 10, 2011, Pages 3661-3673

  Huang, Wei Ching ^a   Tsai, Cheng Chieh ^a,b   Chen, Chia Ling ^a   Chen, Tsai Yun ^a   Chen, Ya Ping ^a   Lin, Yee Shin ^a   Lu, Pei Jung ^a   Lin, Chun Mao ^c   Wang, Shwu Huey ^c   Tsao, Chiung Wen ^b   Wang, Chi Yun ^a   Cheng, Yi Lin ^a   Hsieh, Chia Yuan ^a   Tseng, Po Chun ^a   Lin, Chiou Feng ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Ceramide; Drug resistance; Gatekeeper mutation

Indexed keywords

2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; ANTILEUKEMIC AGENT; BCR ABL PROTEIN; CERAMIDE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; GNF 2; IMATINIB; MIGLUSTAT; NILOTINIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

1-DEOXYNOJIRIMYCIN; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CERAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; GENES, ABL; GLUCOSYLTRANSFERASES; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOGLOBULIN G; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MELPHALAN; MICE; MICE, SCID; MORPHOLINES; MUTATION; NEOPLASMS, EXPERIMENTAL; PYRIMIDINES; TRANSPLANTATION, HETEROLOGOUS;

PYRONIA TITHONUS;

EID: 80053917915     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.10-180190     Document Type: Article

References (57)

1. Bartram, C. R., de Klein, A., Hagemeijer, A., van Agthoven, T., Geurts van Kessel, A., Bootsma, D., Grosveld, G., Ferguson- Smith, M. A., Davies, T., Stone, M., Heisterkamp, N., Stephenson, J. R., and Groffen, J. (1983) Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306, 277-280
2. Groffen, J., Stephenson, J. R., Heisterkamp, N., de Klein, A., Bartram, C. R., and Grosveld, G. (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36, 93-99
3. Ben-Neriah, Y., Daley, G. Q., Mes-Masson, A. M., Witte, O. N., and Baltimore, D. (1986) The chronic myelogenous leukemiaspecific P210 protein is the product of the bcr/abl hybrid gene. Science 233, 212-214
4. Smith, K. M., Yacobi, R., and Van Etten, R. A. (2003) Autoinhibition of Bcr-Abl through its SH3 domain. Mol. Cell. 12, 27-37
5. Deininger, M. W., Goldman, J. M., and Melo, J. V. (2000) The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356
6. Ren, R. (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5, 172-183
7. Kantarjian, H. M., Cortes, J. E., O'Brien, S., Giles, F., Garcia- Manero, G., Faderl, S., Thomas, D., Jeha, S., Rios, M. B., Letvak, L., Bochinski, K., Arlinghaus, R., and Talpaz, M. (2003) Imatinib mesylate therapy in newly diagnosed patients with Philadelphiachromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 101, 97-100
8. Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W., Silver, R. T., Goldman, J. M., Stone, R. M., Cervantes, F., Hochhaus, A., Powell, B. L., Gabrilove, J. L., Rousselot, P., Reiffers, J., Cornelissen, J. J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J. L., Radich, J. P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L., and Larson, R. A. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417
9. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880
10. Druker, B. J. (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112, 4808-4817
11. Deininger, M., Buchdunger, E., and Druker, B. J. (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640-2653
12. Adrian, F. J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P., Mestan, J., Fabbro, D., and Gray, N. S. (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2, 95-102
13. O'Hare, T., Eide, C. A., and Deininger, M. W. (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110, 2242-2249
14. Kockeritz, L., Doble, B., Patel, S., and Woodgett, J. R. (2006) Glycogen synthase kinase-3-an overview of an over-achieving protein kinase. Curr. Drug Targets 7, 1377-1388
15. Jope, R. S., and Johnson, G. V. (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29, 95-102
16. Maurer, U., Charvet, C., Wagman, A. S., Dejardin, E., and Green, D. R. (2006) Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 21, 749-760
17. Ding, Q., He, X., Xia, W., Hsu, J. M., Chen, C. T., Li, L. Y., Lee, D. F., Yang, J. Y., Xie, X., Liu, J. C., and Hung, M. C. (2007) Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res. 67, 4564-4571
18. Luo, J. (2009) Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett. 273, 194-200
19. Rayasam, G. V., Tulasi, V. K., Sodhi, R., Davis, J. A., and Ray, A. (2009) Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol. 156, 885-898
20. Huang, W. C., Lin, Y. S., Chen, C. L., Wang, C. Y., Chiu, W. H., and Lin, C. F. (2009) Glycogen synthase kinase-3beta mediates endoplasmic reticulum stress-induced lysosomal apoptosis in leukemia. J. Pharmacol. Exp. Ther. 329, 524-531
21. Pushkareva, M., Obeid, L. M., and Hannun, Y. A. (1995) Ceramide: an endogenous regulator of apoptosis and growth suppression. Immunol. Today 16, 294-297
22. Saddoughi, S. A., Song, P., and Ogretmen, B. (2008) Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell. Biochem. 49, 413-440
23. Hannun, Y. A., and Obeid, L. M. (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell. Biol. 9, 139-150
24. Baran, Y., Salas, A., Senkal, C. E., Gunduz, U., Bielawski, J., Obeid, L. M., and Ogretmen, B. (2007) Alterations of ceramide/ sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J. Biol. Chem. 282, 10922-10934
25. Li, Q. F., Huang, W. R., Duan, H. F., Wang, H., Wu, C. T., and Wang, L. S. (2007) Sphingosine kinase-1 mediates BCR/ABLinduced upregulation of Mcl-1 in chronic myeloid leukemia cells. Oncogene 26, 7904-7908
26. Salas, A., Ponnusamy, S., Senkal, C. E., Meyers, M., Selvam, S. P., Saddoughi, S. A., Apohan, E., Sentelle, R. D., Smith, C., Gault, C. R., Obeid, L. M., El-Shewy, H. M., Oaks, J., Santhanam, R., Marcucci, G., Baran, Y., Mahajan, S., Fernandes, D., Stuart, R., Perrotti, D., and Ogretmen, B. (2011) Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood 117, 5941-5952
27. Lin, C. F., Chen, C. L., Chiang, C. W., Jan, M. S., Huang, W. C., and Lin, Y. S. (2007) GSK-3beta acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis. J. Cell Sci. 120, 2935-2943
28. Tsai, C. C., Kai, J. I., Huang, W. C., Wang, C. Y., Wang, Y., Chen, C. L., Fang, Y. T., Lin, Y. S., Anderson, R., Chen, S. H., Tsao, C. W., and Lin, C. F. (2009) Glycogen synthase kinase-3beta facilitates IFN-gamma-induced STAT1 activation by regulating Src homology-2 domain-containing phosphatase 2. J. Immunol. 183, 856-864
29. Chen, C. L., Lin, C. F., Chang, W. T., Huang, W. C., Teng, C. F., and Lin, Y. S. (2008) Ceramide induces p38 MAPK and JNK activation through a mechanism involving a thioredoxin-interacting protein-mediated pathway. Blood 111, 4365-4374
30. Schiffmann, S., Sandner, J., Schmidt, R., Birod, K., Wobst, I., Schmidt, H., Angioni, C., Geisslinger, G., and Grosch, S. (2009) The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis. J. Lipid Res. 50, 32-40
31. Shaner, R. L., Allegood, J. C., Park, H., Wang, E., Kelly, S., Haynes, C. A., Sullards, M. C., and Merrill, A. H., Jr. (2009) Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers. J. Lipid Res. 50, 1692-1707
32. Wang, S. H., Yang, W. B., Liu, Y. C., Chiu, Y. H., Chen, C. T., Kao, P. F., and Lin, C. M. (2011) A potent sphingomyelinase inhibitor from Cordyceps mycelia contributes its cytoprotective effect against oxidative stress in macrophages. J. Lipid Res. 52, 471-479
33. Skorski, T., Kanakaraj, P., Nieborowska-Skorska, M., Ratajczak, M. Z., Wen, S. C., Zon, G., Gewirtz, A. M., Perussia, B., and Calabretta, B. (1995) Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86, 726-736
34. Skorski, T., Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., Wasik, M. A., Tsichlis, P. N., and Calabretta, B. (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16, 6151-6161
35. Zhang, J., Adrian, F. J., Jahnke, W., Cowan-Jacob, S. W., Li, A. G., Iacob, R. E., Sim, T., Powers, J., Dierks, C., Sun, F., Guo, G. R., Ding, Q., Okram, B., Choi, Y., Wojciechowski, A., Deng, X., Liu, G., Fendrich, G., Strauss, A., Vajpai, N., Grzesiek, S., Tuntland, T., Liu, Y., Bursulaya, B., Azam, M., Manley, P. W., Engen, J. R., Daley, G. Q., Warmuth, M., and Gray, N. S. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501-506
36. Platt, F. M., Neises, G. R., Dwek, R. A., and Butters, T. D. (1994) N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem. 269, 8362-8365
37. Bieberich, E., Freischutz, B., Suzuki, M., and Yu, R. K. (1999) Differential effects of glycolipid biosynthesis inhibitors on ceramide- induced cell death in neuroblastoma cells. J. Neurochem. 72, 1040-1049
38. Rosen, H., and Goetzl, E. J. (2005) Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol. 5, 560-570
39. Xie, S., Wang, Y., Liu, J., Sun, T., Wilson, M. B., Smithgall, T. E., and Arlinghaus, R. B. (2001) Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20, 6188-6195
40. Ten Hoeve, J., Arlinghaus, R. B., Guo, J. Q., Heisterkamp, N., and Groffen, J. (1994) Tyrosine phosphorylation of CRKL in Philadelphia leukemia. Blood 84, 1731-1736
41. Mian, A. A., Oancea, C., Zhao, Z., Ottmann, O. G., and Ruthardt, M. (2009) Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. Leukemia 23, 2242-2247
42. Sawafuji, K., Miyakawa, Y., Weisberg, E., Griffin, J. D., Ikeda, Y., and Kizaki, M. (2003) Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways. Leuk. Lymphoma 44, 1987-1996
43. Samanta, A. K., Lin, H., Sun, T., Kantarjian, H., and Arlinghaus, R. B. (2006) Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 66, 6468-6472
44. Coluccia, A. M., Vacca, A., Dunach, M., Mologni, L., Redaelli, S., Bustos, V. H., Benati, D., Pinna, L. A., and Gambacorti-Passerini, C. (2007) Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 26, 1456-1466
45. Aichberger, K. J., Mayerhofer, M., Krauth, M. T., Skvara, H., Florian, S., Sonneck, K., Akgul, C., Derdak, S., Pickl, W. F., Wacheck, V., Selzer, E., Monia, B. P., Moriggl, R., Valent, P., and Sillaber, C. (2005) Identification of mcl-1 as a BCR/ABLdependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105, 3303-3311
46. Puissant, A., Colosetti, P., Robert, G., Cassuto, J. P., Raynaud, S., and Auberger, P. (2010) Cathepsin B release after imatinibmediated lysosomal membrane permeabilization triggers BCRABL cleavage and elimination of chronic myelogenous leukemia cells. Leukemia 24, 115-124
47. Gouaze, V., Liu, Y. Y., Prickett, C. S., Yu, J. Y., Giuliano, A. E., and Cabot, M. C. (2005) Glucosylceramide synthase blockade downregulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res. 65, 3861-3867
48. Vunnam, R. R., and Radin, N. S. (1980) Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. Chem. Phys. Lipids 26, 265-278
49. Rani, C. S., Abe, A., Chang, Y., Rosenzweig, N., Saltiel, A. R., Radin, N. S., and Shayman, J. A. (1995) Cell cycle arrest induced by an inhibitor of glucosylceramide synthase. Correlation with cyclin-dependent kinases. J. Biol. Chem. 270, 2859-2867
50. Abe, A., Radin, N. S., Shayman, J. A., Wotring, L. L., Zipkin, R. E., Sivakumar, R., Ruggieri, J. M., Carson, K. G., and Ganem, B. (1995) Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J. Lipid Res. 36, 611-621
51. Lee, L., Abe, A., and Shayman, J. A. (1999) Improved inhibitors of glucosylceramide synthase. J. Biol. Chem. 274, 14662-14669
52. Basu, M., Dastgheib, S., Girzadas, M. A., O'Donnell, P. H., Westervelt, C. W., Li, Z., Inokuchi, J., and Basu, S. (1998) Hydrophobic nature of mammalian ceramide glycanases: purified from rabbit and rat mammary tissues. Acta Biochim. Pol. 45, 327-342
53. Ottmann, O. G., Druker, B. J., Sawyers, C. L., Goldman, J. M., Reiffers, J., Silver, R. T., Tura, S., Fischer, T., Deininger, M. W., Schiffer, C. A., Baccarani, M., Gratwohl, A., Hochhaus, A., Hoelzer, D., Fernandes-Reese, S., Gathmann, I., Capdeville, R., and O'Brien, S. G. (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100, 1965-1971
54. Tamborini, E., Bonadiman, L., Greco, A., Albertini, V., Negri, T., Gronchi, A., Bertulli, R., Colecchia, M., Casali, P. G., Pierotti, M. A., and Pilotti, S. (2004) A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127, 294 -299
55. Tamborini, E., Pricl, S., Negri, T., Lagonigro, M. S., Miselli, F., Greco, A., Gronchi, A., Casali, P. G., Ferrone, M., Fermeglia, M., Carbone, A., Pierotti, M. A., and Pilotti, S. (2006) Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene 25, 6140-6146
56. Von Bubnoff, N., Sandherr, M., Schlimok, G., Andreesen, R., Peschel, C., and Duyster, J. (2005) Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 19, 286-287
57. Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., Cross, N. C., Tefferi, A., Malone, J., Alam, R., Schrier, S. L., Schmid, J., Rose, M., Vandenberghe, P., Verhoef, G., Boogaerts, M., Wlodarska, I., Kantarjian, H., Marynen, P., Coutre, S. E., Stone, R., and Gilliland, D. G. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201-1214